How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Anthropic got the ball rolling on thinking about a pause on AI-builds-AI. I clarify the ins and outs. An AI Insider analysis and scoop.

Industry chiefs say a looming breakthrough might deliver superintelligence. Safety experts say we’re not ready for it. Read ...

Casar said the U.S. government can't sit by idly and do nothing. It needs to do something to address the enormous impact of ...

A Generalized Recursive Regular Expression Synthesis Framework" by Professor Sangki Ko's research team from the Depa ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Add Yahoo as a preferred source to see more of our stories on Google. logos of OpenAI Anadolu via Getty Images There’s interesting news coming from Sam Altman’s empire, a firm known for innovating as ...